ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 50,000 Shares

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $12.31, for a total value of $615,500.00. Following the transaction, the director now directly owns 210,346 shares in the company, valued at $2,589,359.26. The trade was a 19.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Laura Shawver also recently made the following trade(s):

• On Monday, January 6th, Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $11.10, for a total transaction of $555,000.00.
• On Monday, December 2nd, Laura Shawver sold 97,244 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $13.56, for a total transaction of $1,318,628.64.
• On Wednesday, December 4th, Laura Shawver sold 14,772 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $13.75, for a total transaction of $203,115.00.

ARS Pharmaceuticals Price Performance

SPRY opened at $12.52 on Wednesday. ARS Pharmaceuticals, Inc. has a 52-week low of $6.26 and a 52-week high of $18.51. The business’s fifty day moving average is $12.44 and its 200-day moving average is $13.14.

Wall Street Analysts Forecast Growth

SPRY has been the subject of a number of research analyst reports. Leerink Partners boosted their price objective on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Raymond James upped their price objective on ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 14th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $30.00 target price on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Four equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $26.00.

Institutional Investors Weigh In On ARS Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of SPRY. Barclays PLC lifted its holdings in shares of ARS Pharmaceuticals by 189.7% during the 3rd quarter. Barclays PLC now owns 111,666 shares of the company’s stock worth $1,618,000 after acquiring an additional 73,127 shares during the period. First Turn Management LLC acquired a new stake in shares of ARS Pharmaceuticals in the 3rd quarter valued at $8,603,000. Royce & Associates LP increased its stake in shares of ARS Pharmaceuticals by 7.1% in the 3rd quarter. Royce & Associates LP now owns 691,455 shares of the company’s stock valued at $10,026,000 after purchasing an additional 45,755 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of ARS Pharmaceuticals during the 3rd quarter worth $2,584,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of ARS Pharmaceuticals by 766.1% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 234,537 shares of the company’s stock worth $3,401,000 after buying an additional 207,456 shares during the last quarter. Institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.